Microbot Medical announces the participation of a key opinion leader in the endovascular robotics space in the following webinar series “MBOT Direct Access”

Microbot Medical announces the participation of a key opinion leader in the endovascular robotics space in the following webinar series “MBOT Direct Access”

Microbot Medical Inc.

The webinar, suitable for all stakeholders interested in the future of intravascular robotics, will take place on Wednesday, December 21, 2022, at 1:00 PM ET

Renowned Miami-based interventional oncologist Dr. Ribal Gandhi will share his personal experiences having completed more than 100 endovascular robotic surgeries

HINGHAM, MA, Dec. 14, 2022 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), developer of the LIBERTY® Robotic System, the first fully disposable robotic vascular system, announced that after the success of the newly launched “Access-Ability Live by MBOT”, the next episode directed to all stakeholders will be held. Interested in the Robotic Intravascular Space, on Wednesday, December 21, 2022 at 1:00 p.m. ET, hosted by the company’s Medical Director, Dr. Eyal Morag.

Dr. Morag’s guest speaker will be Dr. Ripal Gandhi, an interventional oncologist and member of the Miami Heart and Vascular Institute and the Miami Cancer Institute team of physicians where he specializes in minimally invasive treatments for peripheral vascular disease, cancer and other diseases. He has a history of being an innovator in the field of interventional robotics, specifically in the field of endovascular. Dr. Gandhi, a robotics pioneer with significant experience in the use of endovascular surgical robotic systems, will share his personal experiences using a number of different endovascular robotic systems while addressing the current and future landscapes of endovascular procedures and the role robots should play in them.

The “Direct accessibility from MBOT” The webinar series focuses on key topics in healthcare and the endovascular space. Each month, the company will partner with industry leaders, such as physicians, hospital administrators, entrepreneurs, technicians, and financial experts for a lively discussion and Q&A session to address the most important topics related to endovascular procedures.

You can register for the next webinar here: https://us06web.zoom.us/j/87239550988

About Microbot Medical

Microbot Medical Inc. (NASDAQ:MBOT) is a preclinical medical device company that specializes in transformational microrobot technologies, primarily focused on both natural and artificial lumens within the human body. Microbot’s existing proprietary technology platforms provide the foundation for the development of a multi-generation pipeline portfolio (MGPP).

Microbot Medical was founded in 2010 by Harel Gadot, Professors Moshe Shoham, and Yossi Bornstein with the goal of improving patient clinical outcomes and increasing access through the use of microbot technologies. More information about Microbot Medical is available at www.microbotmedical.com http://www.microbotmedical.com.

safe haven

Statements made in this press release or by members of Microbot’s management team and others about Access-Ability Live, regarding future financial and/or operational results, future growth in clinical research, technology and development and potential opportunities for Microbot Medical Inc. and its affiliates, together with other statements about expectations, beliefs, goals, plans or future prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the federal securities laws. Any statements that are not historical facts (including, but not limited to, statements containing words such as “will,” “believe,” “plan,” “expect,” “expect,” and “estimates”) should also be considered forward-looking. data. Forward-looking statements involve risks and uncertainties, including, but not limited to, market conditions, risks inherent in the development and/or commercialization of potential products, including LIBERTY’s technologies and One & Done™, and the results of its studies to evaluate LIBERTY’s, One &’s technologies. Done™ and other current and future technologies, any failure or inability to designate clinicians and clinicians to act as primary investigators for regulatory studies, which could adversely affect or delay such studies, uncertainty in the outcome of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, and a lack of The certainty resulting from the COVID-19 pandemic, the need and ability to obtain future capital, and the maintenance of intellectual property rights. Additional information about the risks to Microbot Medical can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s website at www.sec.gov. Microbot Medical disclaims any intention or obligation to update these forward-looking statements, except as required by law.

The statements, views, and opinions expressed by guests of the MBOT Access-Ability Live webcast series are theirs alone, and do not necessarily reflect the statements, views, or opinions of employers, organizations, and/or associations, or Microbot Medical Inc. affiliated companies. Some of the Access-Ability Guests are members of the Scientific Advisory Board (SAB) for Microbot or paid consultants for Microbot, and have received compensation for their services to Microbot.

Investor contact:
Michael Polivio
EVC group
mpolyviou@evcgroup.com | 732-933-2754

#Microbot #Medical #announces #participation #key #opinion #leader #endovascular #robotics #space #webinar #series #MBOT #Direct #Access

Leave a Comment

Your email address will not be published. Required fields are marked *